Clinical Trial Update: The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a four-drug regimen (didanosine, stavudine, delavirdine, MKC-442) in HIV infection patients who have not responded to protease inhibito…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Delavirdine (delavirdine)
• Didanosine (didanosine)
• MKC-442 (MKC-442)
• stavudine (stavudine)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: HIV Infections | Phase 2 | Status: TERMINATED